We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics

118 hedge funds and large institutions have $85.9M invested in Lineage Cell Therapeutics in 2019 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 44 increasing their positions, 20 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 20

76% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 17

65% more capital invested

Capital invested by funds: $52.1M → $85.9M (+$33.8M)

18% more call options, than puts

Call options by funds: $98K | Put options by funds: $83K

12% more funds holding

Funds holding: 105118 (+13)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1.08% less ownership

Funds ownership: 44.95%43.87% (-1.1%)

Holders
118
Holders Change
+13
Holders Change %
+12.38%
% of All Funds
2.55%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
30
Increased
44
Reduced
20
Closed
17
Calls
$98K
Puts
$83K
Net Calls
+$15K
Net Calls Change
-$5K
Name Holding Trade Value Shares
Change
Change in
Stake
FANJ
126
Financial Architects (New Jersey)
New Jersey
+$101 +81 New
WAM
127
Wealthspire Advisors (Maryland)
Maryland
+$109 +88 New
First Manhattan
128
First Manhattan
New York
+$117 +94 New
KPW
129
Kore Private Wealth
New York
+$183 +147 New